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Abstract Epithelial cells lining the adult colon do not
normally express gastrin-releasing peptide (GRP) or its
receptor (GRPR). In contrast, GRP/GRPR can be aberrantly
expressed in human colorectal cancer (CRC) including Caco-
2 cells. We have previously shown that GRPR activation
resultsintheup-regulationofHP1β,anepigeneticmodifierof
gene transcription. The aim of this study was to identify the
genes whose expression is altered by HP1β subsequent to
GRPR activation. We determined HP1β binding positions
throughout the genome using chromatin immunoprecipitation
followed by massively parallel DNA sequencing (ChIP-seq).
AfterexposuretoGRP,weidentified9,625genomicpositions
occupied by HP1β. We performed gene microarray analysis
on Caco-2 cells in the absence and presence of a GRPR
specificantagonistaswellassiRNAtoHP1β.The expression
of 97 genes was altered subsequent to GRPR antagonism,
while the expression of 473 genes was altered by HP1β
siRNA exposure. When these data were evaluated in concert
with our ChIP-seq findings, 9 genes showed evidence of
possible altered expression as a function of GRPR signaling
via HP1β. Of these, genomic PCR of immunoprecipitated
chromatin demonstrated that GRPR signaling affected the
expression of IL1RAPL2, FAM13A, GBE1, PLK3, and
SLCO1B3. These findings provide the first evidence by
whichGRPRaberrantlyexpressed inCRC might affecttumor
progression.
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Introduction
Gastrin-releasing peptide (GRP) is a 27 amino acid peptide
hormone that acts via a specific 7 transmembrane-spanning
G protein coupled receptor. While GRP and the GRP
receptor (GRPR) are not normally expressed by epithelial
cells lining the colon, both can be aberrantly expressed in
colorectal cancer (CRC) (Carroll et al. 1999; Jensen et al.
2008). Although GRP acts as a modest mitogen in a variety
of cancer cell lines when studied in vitro, the data from in
vivo studies are less clear and do not necessarily suggest
that this peptide hormone acts as a clinically significant
growth factor [reviewed in (Jensen et al. 2001)]. Yet few
studies have been performed to identify the mechanisms
whereby GRP alters CRC behavior independently of its
modest ability to increase cell proliferation.
We previously used a proteomics approach to attempt to
identify the mediators of GRP’s actions in CRC (Ruginis et
al. 2006). In that study, we used two-dimensional gel
electrophoresis followed by matrix-assisted laser desorp-
tion/ionization time-of-flight (MALDI-TOF) mass spec-
trometry to identify proteins whose expression was
increased as a result of GRP signaling. One of the proteins
so identified was a member of the heterochromatin
associated protein family, which we recently showed was
heterochromatin protein 1β (Tell et al. 2011).
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telomeres, and specific sites within euchromatin
[reviewed in (Dialynas et al. 2008)] and act to modulate
gene transcription (Grewal and Jia 2007). Although HP1
proteins primarily repress gene transcription in normal
tissues by interacting with methylated histones, they can
also activate gene transcription, particularly in malignancy
(Grewal and Jia 2007). In the few cancers studied,
however, the in vitro data regarding HP1 function has
been conflicting. For instance, HP1α is down-regulated in
invasive breast cancer cell lines as compared to those that
are not invasive (Kirschmann et al. 2000). Increasing
HP1α expression in cells that normally express little of
this protein decreased invasiveness, whereas decreasing
the expression of this protein by RNAi in cells otherwise
replete with HP1α increased their invasiveness (Norwood
et al. 2006). Similarly, various HP1 isoforms have been
shown to correlate with decreased invasiveness of other
cancer cell lines including those from papillary thyroid
(Wasenius et al. 2003) ,m e l a n o m a( N i s h i m u r ae ta l .2006),
ovarian (Maloney et al. 2007), and embryonal brain
cancers (Pomeroy et al. 2002).
In contrast, HP1 has also been suggested to have
deleterious effects in cancer cells. For instance, whereas
no HP1 isoforms are detected in adult neutrophils, all three
isoforms are up-regulated in the granulocytes of patients
with acute myeloid leukemia and chronic myeloid leukemia
(Dialynas et al. 2008). A single study has shown that HP1γ
is up-regulated in human CRC, and that inhibiting this
isoform’s expression in CRC cell lines decreases tumor cell
growth (Takanashi et al. 2009). Hence, it appears that HP1
proteins can have variable effects in different cancers.
With our identification of a specific ligand—gastrin-
releasing peptide—altering the expression of a specific HP1
isoform—HP1β—it is now possible to determine what
genes are regulated by this signaling pathway in colon
cancer. In this study, we show that GRP-induced expression
of HP1β decreases the expression of but one gene, but
increases the expression of four genes. Based on what is
known about these five proteins, our data provide an
important window into possible mechanisms whereby
aberrantly expressed GRP/GRPR alter CRC behavior, as
well as identifies potential therapeutic targets for the
treatment of this type of cancer.
Methods
Materials
Caco-2 cells (with non-functional p53) were all obtained
from ATCC (Rockville, MD) and maintained as recom-
mended. RNA Stat-60, isopropanol, chloroform, and
DEPC water were all purchased from Fisher Biosciences
(Pittsburgh, PA). SiRNA targeted to the relevant mRNA
w a so b t a i n e df r o mA m b i o n( A u s t i n ,T X )a n du s e da s
directed. Affymetrix human U133 Microarray Analysis
Chips were purchased from Affymetrix (Santa Clara,
CA). Anti-HP1Hsβ is a rabbit polyclonal antibody
directed between residues 150 and the C terminus of
the human, mouse, and marsupial protein and was
purchased from AbCAM (Cambridge, MA). Anti-RNA
polymerase II is a mouse polyclonal antibody directed
against the synthetic peptide YSPTSPPS purchased
through Active Motif (Carlsbad, CA). RC-30965 was
obtained from Sigma Aldrich (St. Louis, MO).
RNA isolation
Total RNA was isolated from the relevant cells using RNA-
Stat 60 according to the manufacturer’s specifications.
Chloroform was added to solutions before being centri-
fuged at 12,000×g for 15 min at 4°C. The upper aqueous
layer was retrieved and mixed with isopropanol and
subsequently centrifuged at 12,000×g for 10 min at 4°C.
The pellet was washed with 75% ethanol, centrifuged at
7,500×g for 5 min at 4°C, air-dried, and resuspended in
water. mRNA was isolated using Qiagen (Valencia, CA)
and Invitrogen (Carlsbad, CA) kits according to manufac-
turers’ instructions.
Microarray analysis
After confirmation of sample quality as described above,
RNA samples were hybridized using a human U133A
Microarray Chip. Array data were analyzed with Dchip, a
model-based method for expression analysis (http://www.
Dchip.org). The minimum expression was rounded up to
10, the average of noise in our hybridization experiments.
Samples were separated into two replicates (Antagonist,
CBX1 siRNA, and Control) done at similar time points
with stock matched reagents.
Real time RT-PCR
Real time PCR was carried out on cDNA using the Applied
Biosystems Fast7500 Sequencer (Carlsbad, Ca) in order to
confirm the knockdown of the target genes. Taqman real
time PCR primers from Applied Biosystems were used
along with the Applied Biosystems Gene Expression
Master Mix. Samples were quantified using a Nanodrop
ND-1000 Spectrophotometer (Wilmington, DE) and diluted
accordingly. Each sample was further diluted in a stepwise
fashion and loaded into 96 well plates along with the reaction
reagents. Each experimental run was load controlled against
the 18S ribosomal subunit.
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CaCo-2 cells were sonicated with a Fisher Sonic Dismem-
brator 60 (Pittsburgh, Pa) for three 20-s pulses interspersed
with one minute rest times, followed by immunoprecipita-
tion using the ChIP-it Express Kit (Active Motif, Carlsbad,
Ca). The ChIP-It control kit “Human” was used as positive
control. The positive control antibody used was a mouse
monoclonal antibody targeted against the synthetic peptide
YSPTSPPS corresponding to RNA polymerase II. Positive
control primers were designed to target GAPDH, creating a
166-bp product upon PCR. The forward primer for GAPDH
was 5′-TAC TAG CGG TTT TAC GGG CG-3′. The reverse
was 5′-TCG AAC AGG AGG AGC AGA GAG CGA-3′.
For immunoprecipitation of HP1β, a rabbit polyclonal
antibody directed to amino acids 61–100 of the protein was
used (Santa Cruz Biotechnologies, Santa Cruz, CA).
Following immunoprecipitation, genomic DNA was isolat-
ed using a Qiagen DNA Micro Kit (Valencia, Ca). We used
the gene for ARHGAP9 as a positive control for HP1β
chromatin immunoprecipitation since this gene showed
strong alteration in expression without showing evidence
of altered expression subsequent to altered GRPR signaling,
as determined by microarray, indicating that HP1β was
likely binding in the vicinity of this gene. PCR primers
(Invitrogen, Carlsbad, Ca) targeting the gene ARHGAP9
were 5′-GCA GTC CCA TGC ACA AGA T-3′ (forward)
and 5′-TGA GTG GAT TAA CCC CTG CT-3′ (reverse).
Chromatin immunoprecipitation sequencing
Samples for HP1β and IGG negative control were prepared
via ChIP. Sequencing was performed using the Oligonu-
cleotide Ligation and Detection (SOLiD) next generation
sequencer (Applied Biosystems, Foster City, CA). Sequenc-
ing was carried out with 12 million 35 base pair reads.
Sequence alignment was performed using the BOWTIE
aligner (Langmead et al. 2009), modified for color space
reads. Experimental samples were compared against the
negative control using a Poisson Distribution as assigned
by the MACS aligner (Zhang et al. 2008). These reads were
converted to .BED format and uploaded to the UCSC
Genome Browser for peak identification.
Genomic PCR of chromatin immunoprecipitated DNA
Genomic DNA was immunoprecipitated after exposure to
antibodies directed against HP1β or H3K9, the latter
employed because methylated lysine 9 is a known binding
target for HP1β (Bannister et al. 2001); as a control,
immunoprecipitation was also performed using antibodies
to IgG. As a further control, the same immunoprecipitations
experiments were performed against cells whose ability to
express GRPR was eliminated by siRNA as previously
described (Tell et al. 2011). DNA was then subject to PCR
with primers targeting genes determined to be both
expressed differentially during microarray analysis and
displaying a ChIP Sequencing Peak in the local area.
Primer constructs were created using Invitrogen Oligoper-
fect Primer Generator. The sequences for each primer were
as follows: SLC0B13 (forward): 5′-ATG ACC CAA ATG
CCT GAA-3′; (reverse): 5′-TGG AGA AAA GGG AAC
GCT-3′. IL1RAPL2 (forward): 5′-TAA TTG CCA CCG
ACT TCT CC-3′; (reverse): 5′-TGA AGG TAC TTC CCC
TGT GG-3′. GBE1 (forward): 5′-GCA CTC TGG AGG
TGA GAA GG-3′; (reverse) 5′-AGA ATG CGC TGT GTT
GTC TG-3′. PLOD2 (forward): 5′-ATG AAT TTT GGC
ACC GTG A-3′; (reverse): 5′-AGC CTT GCT TCT TCC
GTT TT-3′. FAM13A1 (forward): 5′-CAT TGG ACC AGC
CAG TTT C-3′; (reverse): 5′-CCA AGG ACA GTG GGT
TCT GT-3′. PLK3 (forward): 5′-CCT CTG GAA GAC
TGC TGA CC-3′; (reverse): 5′-CTC ACG AGG GCA
AAC TTC TC-3′. CFHR1P (forward): 5′-TGG AGT GCA
ATG GTG TGA TT-3′; (reverse) 5′-GAG TTC GAG ACC
AGC CTG AC-3′. CFH (forward): 5′-TTC TTG AAG AGC
AGT CTT TTG G-3′; (reverse) 5′-AGG AAA GCA AAC
CTC CTC CA-3′.
Results
Effect of GRP/GRPR signaling via HP1β as determined
by microarray analysis
We previously showed that GRP/GRPR signaling in colon
cancer cell lines altered the protein level of HP1β (Ruginis
et al. 2006; Tell et al. 2011). Since HP1β is an epigenetic
modifier of gene transcription, we next determined which
genes had altered expression as a result of both GRPR
activation and HP1β expression. To do this, we isolated
RNA from GRP/GRPR-expressing Caco-2 cells alone or
from cells that had been exposed to the GRPR specific
antagonist RC-3095 or siRNA directed to HP1β.W e
exposed cells to siRNA for 72 h and antagonist for 20 h,
time points we previously have shown to down-regulate
HP1β under either condition (Tell et al. 2011). Control
RNA and RNA extracted from the treated cells was then
exposed to the U133A Microarray Chip, as described in
“Methods”. Using a cut-off of at least a twofold change in
expression, GRPR antagonism resulted in the up-regulation
of 32 genes while siRNA directed to HP1β resulted in the
up-regulation of 164 genes. However, only nine genes were
up-regulated in response to treatment with both reagents
(Fig. 1a; Table 1).
In contrast, and again using a cut-off of a greater than
twofold change in expression, GRPR antagonism resulted
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to HP1β resulted in the down-regulation of 309 genes. Of
these, 54 genes were down-regulated in response to both
treatments (Fig. 1b; Table 2).
Identification of HP1β-regulated genes by ChIP-Seq
Since HP1β is an epigenetic modifier of gene transcription,
we performed chromatin immunoprecipitation against ge-
nomic DNA obtained from GRP/GRPR-expressing Caco-2
cells in order to identify where this protein was binding in
the genome. After genomic DNA extraction and sonication,
rabbit polyclonal antibody directed to amino acids 61–100
of HP1β was used to immunoprecipitate DNA actively
binding this protein. The DNA sequences were then
processed in an Applied Biosystems SOLiD sequencer,
generating 12 million 35 base pair reads. In this fashion, we
determined that GRPR signaling resulted in 9,625 genomic
positions occupied by HP1β.
Combining these data with that obtained by microarray
analysis (above), we determined that two genes occupied
by HP1β were up-regulated in response to the experimental
treatment and that seven genes were down-regulated in
response to this same treatment (Fig. 1; Tables 1 and 2).
This was performed in order to detect a direct linkage
between HP1β induced mRNA alterations and the binding
of the HP1β protein along the nucleosome. In this manner,
those genes directly affected by changes in HP1β binding
were readily determined. Hence, these data suggested that
GRPR signaling via HP1β might be down-regulating two
genes and up-regulating the expression of seven genes. We
next confirmed whether this was the case by performing
genomic PCR for these genes on immunoprecipitated
DNA.
Genomic and real time PCR
We isolated DNA from GRP/GRPR-expressing Caco-2
cells. Immunoprecipitation was performed after exposing
the DNA to antibodies directed against HP1β H3K9
(methylated lysine 9 is a known binding target for HP1β)
or IgG (as control). The same immunoprecipitation experi-
ments were performed on Caco-2 cells that had been
exposed to GRPR siRNA for 72 h, conditions that we have
previously shown completely ablates GRPR expression
(Tell et al. 2011). DNA was then subject to PCR with
intron-exon spanning primers targeting the genes listed in
Tables 1 and 2. Of the two genes potentially down-
regulated subsequent to GRPR signaling via HP1β, gPCR
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Fig. 1 Venn diagram showing the genes up-regulated (a) and down-
regulated (b) in response to treatment with siRNA directed to GRPR
or HP1β, and the genomic positions occupied by HP1β as determined
by ChIP-seq
Table 1 Genes identified by microarray, ChIP-Seq, and genomic PCR as down-regulated subsequent
Gene ID ChIPSeq
detected
gPCR
confirmed
RT-PCR
(fold change)
Pubmed
ID
Chromo Gene description Antag vs.
control (fold
change)
HP1β siRNA
vs. control
(fold change)
IL1RAPL2 Yes Yes 5.6±1.8 26,280 X Interleukin 1 receptor accessory protein-
like 2
4.8 5.4
HSF2BP Yes No n.r. 11,077 21 Heat shock transcription factor 2 binding
protein
2.3 3.2
BOP1 No No n.r. 23,246 3 Block of proliferation 1 3.2 4.0
CYP27B1 No No n.r. 1,594 12 Cytochrome P450, family 27, subfamily
B, polypeptide 1
4.0 5.4
KIR2DL5A No No n.r. 57,292 19 Killer cell immunoglobulin-like receptor,
two domains, long cytoplasmic
4.8 6.4
TNFRSF11B No No n.r. 4,982 8 TNFRSF11B tumor necrosis factor
receptor superfamily, member 11b
3.4 2.6
TNP2 No No n.r. 7,142 16 Transition protein 2 3.1 4.0
UTP20 No No n.r. 27,340 12 TP20, small subunit (SSU) processome
component, homolog
3.2 3.7
WWP2 No No n.r. 11,060 16 WW domain containing E3 ubiquitin protein
ligase 2
3.6 4.6
Antag: GRPR Specific Antagonist RC-3095. Chromo: Chromosome on which gene is located
334 Clin Epigenet (2011) 2:331–338Table 2 Genes identified by microarray, ChIP-Seq, and genomic PCR as up-regulated subsequent to GRPR signaling via HP1β
Gene ID ChIP-
Seq
detected
gPCR
confirmed
RT-PCR
(fold change)
Pubmed
ID
Chromo Gene description Antag vs.
control (fold
change)
HP1β siRNA
vs control
(fold change)
FAM13A Yes Yes 2.4±0.6 10,144 4 Family with sequence similarity 13,
member A
2.4 5.5
GBE1 Yes Yes 3.3± 0.7 2,632 3 Glucan (1,4-alpha-), branching enzyme 1 2.8 4.2
PLK3 Yes Yes 2.8± 0.7 1,263 1 Polo-like kinase 3 2.0 2.6
SLCO1B3 Yes Yes 4.2±2.12 28,234 12 Solute carrier organic anion transporter
family, member 1B3
2.0 3.5
PLOD2 Yes No n.r. 5,352 3 Procollagen lysine, 2-oxoglutarate
5-dioxygenase 2
2.2 5.2
ACSF2 No No n.r. 80,221 17 Acyl-CoA synthetase family member 2 2.1 2.3
AKAP7 No No n.r. 9,465 6 A kinase (PRKA) anchor protein 7 5.0 14.1
APOL1 No No n.r. 8,542 22 apolipoprotein L, 1 2.0 3.0
ARL14 No No n.r. 80,117 3 ADP-ribosylation factor-like 14 2.4 4.6
BCL3 No No n.r. 602 19 B-cell CLL/lymphom a 3 3.4 3.5
BDH2 No No n.r. 56,898 4 3-hydroxybutyrate dehydrogenase,
type 2
2.0 3.1
BNIP3L No No n.r. 665 8 BCL2/adenovirus E1B 19 kDa
interacting protein 3-like
2.4 6.0
CCDC64 No No n.r. 92,558 12 Coiled-coil domain containing 64 2.1 3.0
CDKN1A No No n.r. 12,575 17 Cyclin dependent kinase inhibitor 1A
(P21)
2.5 4.8
CDKN1C No No n.r. 1,028 11 Cyclin dependent kinase inhibitor
1 C (p57, Kip2)
3.3 7.6
CLIC3 No No n.r. 9022 9 Chloride intracellular channel 3 2.7 3.0
CYP3A5P2 No No n.r. 79,424 7 Cytochrome P450, family 3, subfamily
A, polypeptide 5 pseudogene 2
2.2 2.4
DUSP6 No No n.r. 1,848 12 Dual specificity phosphatase 6 2.1 2.5
ENO2 No No n.r. 2,026 12 Enolase 2 (gamma, neuronal) 3.0 4.9
FABP1 No No n.r. 2,168 2 Fatty acid binding protein 1, liver 3.2 2.8
FOSL1 No No n.r. 8,061 11 FOS-like antigen 1 3.0 2.2
FSCN1 No No n.r. 6,624 7 Fascin homolog 1, actin-bundling
protein (Strongylocent rotus purpuratus)
3.1 3.8
FXYD3 No No n.r. 5,349 19 FXYD domain containing ion transport
regulator 3
2.4 4.1
GAL3ST1 No No n.r. 9,514 22 Galactose-3-Osulfotransferase 1 2.0 2.9
GEM No No n.r. 2,669 8 GTP binding protein overexpressed
in skeletal muscle
3.8 5.2
GPR87 No No n.r. 53,836 3 G protein coupled receptor 87 5.3 2.5
HMGCS2 No No n.r. 3,158 1 3-hydroxy-3-methylglutaryl-CoA
synthase 2 (mitochondrial)
2.6 2.6
HRH1 No No n.r. 3,269 3 Histamine receptor H1 2.3 2.9
KDM4B No No n.r. 23,030 19 Lysine (K)-specific demethylase 4B 2.4 2.9
LAMA3 No No n.r. 3,909 18 Laminin, alpha 3 2.4 2.1
LDLR No No n.r. 3,949 19 Low density lipoprotein receptor 2.1 2.7
LGALS1 No No n.r. 3,956 22 Lectin, galactosidebinding, soluble, 1 2.2 2.5
MAFF No No n.r. 23,764 22 v-maf musculoaponeurotic fibrosarcoma
oncogene homolog F
2.0 3.8
NAB2 No No n.r. 4,665 12 NGFI-A binding protein 2
(EGR1 binding protein 2)
2.1 3.2
NDRG1 No No n.r. 10,397 8 N-myc downstream regulated 1 5.7 18.5
NDUFA4L2 No No n.r. 56,901 12 NADH dehydrogenase (ubiquinone) 1
alpha subcomplex, 4-like 2
9.8 9.2
P4HA1 No No n.r. 5,033 10 Prolyl 4-hydroxylase, alpha polypeptide I 3.2 7.9
PDE9A No No n.r. 5,152 21 Phosphodiesterase 9A 2.0 2.5
PER2 No No n.r. 8,864 2 Period homolog 2 (Drosophila) 2.5 3.5
PHLDA1 No No n.r. 22,822 12 Pleckstrin homology-like domain,
family A, member 1
2.2 3.9
PTK6 No No n.r. 5,753 20 PTK6 protein tyrosine kinase 6 2.2 2.4
PTPRH No No n.r. 5,794 19 Protein tyrosine phosphatase,
receptor type, H
2.1 2.3
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protein-like 2 (IL1RAPL2) (Fig. 2). In contrast, of the
seven genes potentially up-regulated subsequent to GRPR
signaling via HP1β, gPCR was successful for 4: family
with sequence similarity 13, member A (FAM13A), glucan
(1,4-alpha-), branching enzyme 1 (GBE1), procollagen
lysine, 2-oxoglutarate 5-dioxygenase 2 (SLCO1B3), and
polo-like kinase 3 (PLK3).
Finally, we confirmed that GRPR signaling actually
altered mRNA expression for these six genes by performing
real time PCR. To do this, we quantified the relevant RNA
in GRP/GRPR-expressing Caco-2 cells and compared that
to what was expressed in cells exposed to GRPR siRNA.
GRPR signaling decreased IL1RAPL2 expression 5.6±1.8-
fold (means±SEM, n=3); and increased the expression of
FAM13A 2.4±0.6-fold, GBE1 3.3± 0.7-fold, PLK3 2.8±0.7-
fold, and SLCO1B3 4.2±2.12-fold (Tables 1 and 2).
Discussion
HP1 consists of a family of evolutionarily conserved
proteins that act to epigenetically alter gene expression. In
cancer, the role of HP1 is not clear: although proteins in this
family appear largely to protect against tumor cell aggres-
siveness and metastasis (Kirschmann et al. 2000; Pomeroy
et al. 2002;N o r w o o de ta l .2004, 2006), worsened
outcomes can also be associated with enhanced HP1
expression (Dialynas et al. 2008; Takanashi et al. 2009).
Likewise, a number of studies have found that GRP/GRPR
expression can have both deleterious as well as beneficial
effects when these proteins are aberrantly expressed in a
variety of malignancies [reviewed in (Jensen et al. 2008)].
Consistent with this dichotomous background, the results of
this study demonstrate that GRP/GRPR signaling via HP1β
can alter the expression of yet other proteins that might be
expected to either improve or worsen the outcome of
patients with CRC. We show that GRPR-induced up-
regulation of HP1β results in the increased expression of
FAM13A, GBE1, PLK3, and SLCO1B3 and the decreased
expression of IL1RAPL2. Each will be reviewed in turn.
FAM13 (family with sequence similarity 13) was isolated
from within a cluster of genes coding for extracellular matrix
proteins involved in integrin–receptor interactions (Cohen et
al. 2004). Genes within this cluster are involved in bone,
mammary gland lobuloalveolar structures, and kidney
function, suggesting that FAM13 likewise might be involved
in the regulation of tissue architecture. This of interest since
we have previously suggested that GRP/GRPR act as
morphogens in CRC [reviewed in (Jensen et al. 2001)],
promoting a better-differentiated tumor phenotype as they
reprise their role in normal gut organogenesis (Carroll et al.
2002). Although there are no data relating to FAM13
expression in colon or colon cancer, it might be that this
protein when expressed might be involved in GRP/GRPR
promotion improved tumor differentiation, a marker of
improved patient outcome.
GBE1 [glucan (1,4-alpha-), branching enzyme 1] defi-
ciency results in glycogen storage disease type IV due to
the accumulation of amylopectin-like polysaccharide caus-
ing cell swelling and death. More recently, it has been noted
that this protein might also act as a morphogen, at least in
the context of normal cardiac development (Lee et al.
2010). In cancer, decreased GBE1 levels are noted in
ovarian cancer (Birch et al. 2008) and longer survival
observed in patients with cervical cancer whose tumors
expressed high levels of this protein (Lando et al. 2009).
Although nothing is known about GBE1 in colon cancer,
GRP/GRPR-induced up-regulation of this protein in this
tumor type might be expected to improve patient outcome.
Table 2 (continued)
Gene ID ChIP-
Seq
detected
gPCR
confirmed
RT-PCR
(fold change)
Pubmed
ID
Chromo Gene description Antag vs.
control (fold
change)
HP1β siRNA
vs control
(fold change)
PTPRR No No n.r. 5,801 12 Protein tyrosine phosphatase,
receptor type, R
6.5 12.0
RARRES1 No No n.r. 5918 3 Retinoic acid receptor responder
(tazarotene induced) 1
2.4 3.8
RHOF No No n.r. 54,509 12 Ras homolog gene family, member F
(in filopodia)
2.1 3.1
SCARF1 No No n.r. 8,578 17 Scavenger receptor class F, member 1 2.5 4.2
SGK1 No No n.r. 6,446 6 Serum/glucoco rticoid regulated kinase 1 2.1 3.2
SERPINB9 No No n.r. 5,272 6 Serpin peptidase inhibitor, clade B
(ovalbumin), member 9
2.5 3.8
SLC11A2 No No n.r. 4,891 12 Solute carrier family 11
8(proton-coupled divalent metal ion)
3.0 3.7
SPAG4 No No n.r. 6,676 20 Sperm associated antigen 4 3.5 4.8
TFF2 No No n.r. 7,032 21 Trefoil factor 2 2.3 2.5
ZNF274 No No n.r. 10,782 19 Zinc finger protein 274 3.1 3.2
336 Clin Epigenet (2011) 2:331–338PLK3 (polio-like kinase 3) is one of four isoforms in a
family of serine/threonine kinases (Johnson et al. 2007).
Although different PLK isoforms in cancer have different
phenotypes, PLK3 appears to promote cell cycle arrest,
apoptosis, and in selected cancers, act as a tumor suppressor
(Dai et al. 2002; Pellegrino et al. 2010). Furthermore, PLK3
knock-out mice develop tumors in various organs at
advanced age (Yang et al. 2008), although none were noted
arising in the colon. Again, GRP/GRPR-induced expression
of PLK3 in CRC would thus be expected to benefit the host.
SLCO1B3 (organic anion transporting polypeptide 1B3;
also known as Organic anion transporting polypeptide 1B3
or OATP1B3) is a member of membrane influx transporters
that normally regulate the uptake of endogenous com-
pounds, but which are also important in mediating drug
absorption [reviewed in (Kalliokoski and Niemi 2009)].
SLCO1B3 is particularly important in regulating the uptake
of taxanes such as the chemotherapeutic drug paclitaxel
(Smith et al. 2005), and thus its expression has positively
correlated with prognosis in a variety of malignancies
including breast (Muto et al. 2007) and prostate (Hamada et
al. 2008). Yet, SLCO1B3 also promotes bile acid uptake in
the colon, and which in a recent study was shown to
activate cyclooxygenase-2 gene transcription (Oshio et al.
2008), in turn known to promote tumor cell proliferation.
Indeed, SLCO1B3 over-expression enhances the survival of
human colon cancer cell lines that harbor wild-type (i.e.,
not mutated) p53. Hence, the impact of SLCO1B3 on
human colon cancers, expressed subsequent to GRPR
signaling via HP1β, remains to be elucidated.
Finally, we showed that GRPR signaling via HP1β
resulted in the down-regulation of IL1RAPL2 (interleukin 1
receptoraccessory protein-like 2). The function ofthisprotein
is not well understood but appears to be important in the
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Fig. 2 Genomic PCR for genes
identified by microarray and
ChIP-seq as regulated by GRPR
signaling via HP1β. Genomic
DNA was extracted from both
wild-type Caco-2 cells (+) and
cells that had been exposed to
GRPR siRNA for 72 h (−) and
immunoprecipitated after
exposure to antibodies directed
against HP1β, H3K9, or IGG.
DNA was then subject to PCR
with primers targeting genes
determined to be both expressed
differentially during microarray
analysis and displaying a ChIP
Sequencing Peak in the local
area
Clin Epigenet (2011) 2:331–338 337function of the central nervous system, with mutations
contained therein associated with autism (Piton et al. 2008).
Overall, then, our findings do not unambiguously
demonstrate what effect GRPR signaling via HP1β might
have on patients with colon cancer. FAM13, GBE1, and
PLK3 all have been previously shown to be involved in
processes that might be expected to improve patient
outcome; whereas SLCO1B3 might be expected to worsen
patient outcome. In contrast, there are no previously
published data for IL1RAPL2 for any malignancy. To
determine what effect any of these proteins have in CRC in
the context of GRPR signaling will therefore require
additional studies.
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